RE:More comments on Biogen's aducanumab If this opinion is on track then it's just more evidence that Elliot's Aducanumab-or-bust strategy is headed for bust. Elliot, if you're reading this and I bet you are, please answer this critique, including the ApoE4 conjecture.
I don't actually agree with this opinion, in particular the "larger picture" paragraph, but I think this paragraph is indicative of broad investor sentiment working against Promis.
The larger picture is this. Amyloid oligomers are only one of several causes of Alzheimer’s disease and they only form when these other causes are present. In ApoE4 carriers who have larger amounts of amyloid in their brain to begin with, oligomers may add to that damage. In these cases, the inhibition or removal of amyloid oligomers may slow down the progression of Alzheimer’s disease closer to the rate experienced by non-carriers. But they do not address the other causes of the disease nor do they prevent or reverse any of the damage done to the brain due to these other factors (such as environmental toxins, psychological stress, and a diet high in sugar and other carbohydrates).